Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-၀.၂၁%
၁,၀၉၁.၅၁
-၂.၃၀
-၀.၂၁%
—၁,၀၉၃.၈၁၁,၀၉၆.၅၂၁,၁၀၀.၂၂၁,၀၉၁.၅၁——
SIXC
Communications
SIXC
Communications
SIXC
+၀.၂၂%
၆၁၀.၁၁
+၁.၃၄
+၀.၂၂%
—၆၀၈.၇၇၆၀၈.၇၇၆၁၂.၉၇၆၀၈.၇၇——
SIXE
Energy
SIXE
Energy
SIXE
-၁.၃၄%
၁,၂၃၇.၉၈
-၁၆.၈၃
-၁.၃၄%
—၁,၂၅၄.၈၁၁,၂၅၃.၀၁၁,၂၅၃.၈၇၁,၂၂၆.၃၃——
SIXI
Industrials
SIXI
Industrials
SIXI
-၀.၉၃%
၁,၇၄၄.၇၁
-၁၆.၄၀
-၀.၉၃%
—၁,၇၆၁.၁၁၁,၇၆၄.၂၇၁,၇၆၆.၈၈၁,၇၄၄.၇၁——
SIXM
Financials
SIXM
Financials
SIXM
-၀.၃၇%
၆၄၀.၁၈
-၂.၄၀
-၀.၃၇%
—၆၄၂.၅၈၆၄၄.၈၇၆၄၈.၄၈၆၄၀.၁၈——
SIXR
Staples
SIXR
Staples
SIXR
-၀.၁၈%
၈၄၉.၅၈
-၁.၅၅
-၀.၁၈%
—၈၅၁.၁၃၈၅၅.၆၆၈၅၈.၇၅၈၄၅.၅၆——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-၀.၂၃%
၂၁၇.၄၈
-၀.၅၀
-၀.၂၃%
—၂၁၇.၉၈၂၁၇.၉၈၂၁၈.၆၅၂၁၆.၈၈——
SIXT
Technology
SIXT
Technology
SIXT
+၁.၅၂%
၃,၂၆၀.၆၉
+၄၈.၈၆
+၁.၅၂%
—၃,၂၁၁.၈၃၃,၂၂၇.၂၁၃,၂၆၈.၃၈၃,၂၂၆.၅၅——
SIXU
Utilities
SIXU
Utilities
SIXU
-၀.၆၉%
၉၄၂.၄၅
-၆.၅၃
-၀.၆၉%
—၉၄၈.၉၈၉၄၈.၅၈၉၅၇.၈၃၉၄၁.၉၇——
SIXV
Health care
SIXV
Health care
SIXV
-၀.၅၂%
၁,၄၆၆.၈၀
-၇.၇၂
-၀.၅၂%
—၁,၄၇၄.၅၂၁,၄၇၉.၀၃၁,၄၈၁.၀၄၁,၄၆၆.၈၀——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+၀.၂၂%
၂,၃၉၇.၅၀
+၅.၃၈
+၀.၂၂%
—၂,၃၉၂.၁၂၂,၃၉၆.၉၅၂,၄၂၁.၂၂၂,၃၈၂.၃၂——
ALNOV:EPA
Novacyt SA
၀.၃၂ €
-၁၃.၃၈%
(-၀.၀၅၀) 1D
ဧ ၃၀, GMT+၂ ၁၇:၃၅:၁၅  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALNOV...
Open
၀.၃၇ €
High
၀.၃၈ €
Low
၀.၃၂ €
Mkt. cap
၂.၂၉ ကုဋေ
Avg. vol.
၁.၀၈ သိန်း
Volume
၆.၀၁ သိန်း
52-wk high
၀.၇၄ €
52-wk low
၀.၃၂ €
EPS
-၀.၅၀ €
Shares outstanding
၇.၂၆ ကုဋေ
No. of employees
၂၃၄
News stories
From sources across the web
Meyka
Meyka
·
ပြီးခဲ့သည့် ၁၇ နာရီ
ALNOV.PA stock plunges 13.38% on May 1, 2026 amid earnings pressure
Investing.com
Investing.com
·
ပြီးခဲ့သည့် ၁ ရက်
Earnings call transcript: Novacyt’s H2 2025 shows steady growth
Idéal Investisseur
Idéal Investisseur
·
ပြီးခဲ့သည့် ၁ ရက်
Novacyt: Revenue Up 4% to £20M, but Cash Reserves Decline to £19.1M
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees၂၃၄
Founded၂၀၀၆ ဇူ ၃
Headquarters-
Sector-
Websitenovacyt.com
Previous reports
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in GBP
၂၀၂၄ စက်
၂၀၂၄ ဒီ
၂၀၂၅ မတ်
၂၀၂၅ ဇွန်
Revenue
-
-
၄.၉၀ သန်း
၄.၉၀ သန်း
Cost of goods sold
-
-
၁.၆၄ သန်း
၁.၆၄ သန်း
Cost of revenue
-
-
၁.၆၄ သန်း
၁.၆၄ သန်း
Research and development expenses
-
-
၁.၀၂ သန်း
၁.၀၂ သန်း
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
၅.၅၁ သန်း
၅.၅၁ သန်း
Operating expense
-
-
၆.၄၃ သန်း
၆.၄၃ သန်း
Total operating expenses
-
-
၈.၀၈ သန်း
၈.၀၈ သန်း
Operating income
-
-
-၃.၁၈ သန်း
-၃.၁၈ သန်း
Other non operating income
-
-
-၃.၁၀ သောင်း
-၃.၁၀ သောင်း
EBT including unusual items
-
-
-၃.၅၁ သန်း
-၃.၅၁ သန်း
EBT excluding unusual items
-
-
-၃.၁၂ သန်း
-၃.၁၂ သန်း
Income tax expense
-
-
-၁.၃၄ သိန်း
-၁.၃၄ သိန်း
Effective tax rate
-
-
၃.၈၀%
၃.၈၀%
Other operating expenses
-
-
-၉.၇၅ သောင်း
-၉.၇၅ သောင်း
Net income
-
-
-၃.၁၇ သန်း
-၃.၁၇ သန်း
Net profit margin
-
-
-၆၄.၇၆%
-၆၄.၇၆%
Earnings per share
-
-
-
-
Interest and investment income
-
-
၁.၇၇ သိန်း
၁.၇၇ သိန်း
Interest expense
-
-
-၁.၅၄ သိန်း
-၁.၅၄ သိန်း
Net interest expenses
-
-
၂.၃၀ သောင်း
၂.၃၀ သောင်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-၂.၁၇ သန်း
-၂.၁၇ သန်း
Gain or loss from assets sale
-
-
-၁.၄၈ သိန်း
-၁.၄၈ သိန်း
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer